Comparative Pharmacology
Head-to-head clinical analysis: HYDROCODONE BITARTRATE AND ASPIRIN versus QDOLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCODONE BITARTRATE AND ASPIRIN versus QDOLO.
HYDROCODONE BITARTRATE AND ASPIRIN vs QDOLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a mu-opioid receptor agonist; aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and COX-2, reducing prostaglandin synthesis.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
One to two tablets (hydrocodone bitartrate 5-10 mg / aspirin 500 mg) orally every 4-6 hours as needed for pain; maximum daily dose: 8 tablets (hydrocodone 40 mg, aspirin 4000 mg).
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
None Documented
None Documented
Hydrocodone: terminal elimination half-life of approximately 3.8-4.5 hours (range 3.3-4.4 hours in adults) in healthy individuals; prolonged in hepatic impairment and elderly. Aspirin: 15-20 minutes for parent drug; salicylate half-life is dose-dependent (2-3 hours at low doses, up to 15-30 hours at anti-inflammatory doses).
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Hydrocodone: primarily renal (up to 60% as unchanged drug and metabolites, including norhydrocodone, hydromorphone, and conjugates); <10% biliary/fecal. Aspirin: renal excretion of salicylate and its conjugates (salicyluric acid, salicyl phenolic glucuronide, etc.); dose-dependent elimination kinetics.
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Category D/X
Category C
Opioid Agonist
Opioid Agonist